NasdaqHealth CareHealth Care SuppliesS&P SmallCap 600
$87.23
-2.39 (-2.67%)
Close of Nov 06, 2026 · end-of-day data
MMSI 8-K filings in 2026
Every material Form 8-K Merit Medical Systems filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Merit Medical reported third-quarter 2026 revenue of $416.2 million, up 8.4% from a year earlier, and GAAP EPS of $0.70, up 51%. The company raised its full-year 2026 revenue and non-GAAP EPS guidance, and separately disclosed a $45 million cash acquisition of Solo Pace, Inc.
Q3 2026 reported revenue $416.2 million, up 8.4%; organic constant currency revenue up 9%
GAAP gross margin fell to 48.2% from 48.5%; GAAP operating margin rose to 14.1% from 11.1%
Full-year 2026 non-GAAP EPS guidance raised to $4.33-$4.37 from $4.25-$4.35; revenue guidance to $1.635-$1.642 billion from $1.631-$1.643 billion
Solo Pace acquisition completed October 13, 2026 for cash of approximately $45 million
Merit Medical said it eliminated its Chief Operating Officer position in an August 14, 2026 reorganization and named Sheri Lewis Executive Vice President of Global Operations, effective August 31, 2026. Neil W. Peterson, the former COO, became Senior Advisor and has given notice of resignation for good reason effective March 5, 2027. The filing describes a leadership change in the operations function without any reported financial results.
Sheri Lewis appointed EVP of Global Operations effective August 31, 2026, with a $600,000 base salary and $400,000 signing bonus
Lewis's target annual bonus is 60% of base salary, with a maximum of 200%
Neil W. Peterson's COO title was changed to Senior Advisor; his resignation takes effect March 5, 2027
Lewis's agreement provides a lump sum of two times salary plus bonus average if terminated without cause or for good reason after a change of control
Merit Medical reported second-quarter 2026 revenue of $418.8 million, up 10% from a year earlier, and GAAP diluted EPS of $0.65, up from $0.54. The company raised its full-year 2026 revenue guidance to $1.631 billion to $1.643 billion and its non-GAAP EPS guidance to $4.25 to $4.35, both above its April 30, 2026 outlook. Year-to-date operating cash flow and free cash flow both declined, at $110.0 million (down 11%) and $76.6 million (down 14%).
Q2 2026 reported revenue $418.8 million, up 10%; constant currency organic revenue up 9%
GAAP EPS $0.65 vs. $0.54 a year earlier; non-GAAP EPS $1.19, up 18%
2026 revenue guidance raised to $1.631-$1.643 billion; non-GAAP EPS guidance raised to $4.25-$4.35 from $4.01-$4.15
Year-to-date cash flow from operations $110.0 million, down 11%; free cash flow $76.6 million, down 14%
At its annual meeting on May 13, 2026, Merit Medical shareholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, elected four directors, and ratified Deloitte and Touche LLP as auditor for fiscal 2026. The Board also adopted Fifth Amended and Restated Bylaws effective May 14, 2026. The equity plan reserves a maximum of 2,700,000 shares of common stock for awards, which shareholders should weigh when considering future share issuance.
Equity Incentive Plan approved with 48,750,003 votes for and 1,510,844 against; maximum share reserve of 2,700,000 shares
Four directors elected: Martha G. Aronson, Lonny J. Carpenter and Scott R. Ward to 2029 terms; Lynne N. Ward to a 2027 term
Say-on-pay advisory vote passed with 48,835,995 for and 1,415,355 against
Fifth A&R Bylaws, effective May 14, 2026, add remote meeting participation, electronic notice and updated universal proxy provisions
Merit Medical reported first-quarter 2026 revenue of $381.9 million, up 7%, and non-GAAP earnings per share of $0.94, up 9%. The company raised its full-year 2026 revenue forecast slightly and kept its non-GAAP earnings per share forecast unchanged, after accounting for the April 1, 2026 acquisition of View Point Medical, which is expected to dilute 2026 non-GAAP earnings per share by about $0.05.
Q1 2026 revenue was $381.9 million, up 7% from $355.4 million a year earlier; constant currency organic growth was 2.7%, or 3.7% excluding the divested DualCap product line.
GAAP diluted EPS was $0.68 versus $0.49 a year earlier; non-GAAP EPS was $0.94 versus $0.86.
2026 revenue guidance is $1.612 billion to $1.634 billion, up from $1.610 billion to $1.630 billion; non-GAAP EPS guidance is unchanged at $4.01 to $4.15.
The View Point Medical acquisition closed April 1, 2026 for $140 million, of which $90 million was paid in cash at closing.
Merit Medical reported fourth-quarter 2025 revenue of $393.9 million, up 11%, and non-GAAP EPS of $1.04, up 12%. For fiscal 2026 it guided to total revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, implying growth of 6% to 8% and 5% to 8%, respectively.
Q4 2025 GAAP EPS was $0.63, up from $0.46 a year earlier; non-GAAP EPS was $1.04 versus $0.93.
Full-year 2025 revenue was $1.516 billion, up 12%, and non-GAAP EPS was $3.83, up 11%.
2026 guidance: revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, excluding possible effects of trade policies and unannounced acquisitions.
Merit Medical said preliminary, unaudited fourth-quarter 2025 revenue was in the range of $389 million to $395 million, up about 10% to 11% from a year earlier, or 8% to 10% in constant currency. The company also named F. Ann Millner as Board Chair after founder Fred P. Lampropoulos resigned as director and Chair, which matters to shareholders because the company's leadership is changing while full 2025 results and 2026 guidance are still pending.
Preliminary Q4 2025 revenue of about $389 million to $395 million, up about 10% to 11% year over year; constant currency growth of about 8% to 10%
Lampropoulos resigned as director and Chair effective January 4, 2026, citing personal reasons, and is not leaving over any dispute or financial reporting matter
F. Ann Millner, formerly Lead Independent Director, became Chair effective January 5, 2026; the board also reduced its size from eleven to ten members
Full 2025 results and fiscal 2026 guidance are scheduled for release after the close on February 24, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Merit Medical Systems filing is on SEC EDGAR ↗. 8-K briefs of other companies →